[go: up one dir, main page]

YU21100A - Izohinolini kao urokinazni inhibitori - Google Patents

Izohinolini kao urokinazni inhibitori

Info

Publication number
YU21100A
YU21100A YU21100A YU21100A YU21100A YU 21100 A YU21100 A YU 21100A YU 21100 A YU21100 A YU 21100A YU 21100 A YU21100 A YU 21100A YU 21100 A YU21100 A YU 21100A
Authority
YU
Yugoslavia
Prior art keywords
isoquinolines
urokinase inhibitors
urokinase
inhibitors
upa
Prior art date
Application number
YU21100A
Other languages
English (en)
Inventor
Christopher Gordon Barber
Peter Dickinson Roger
Vincent Fish Paul
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU21100A publication Critical patent/YU21100A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Jedinjenja formule (I) i njihove farmaceutski prihvatljive soli, gde jedan od R1 i R2 je H a drugi je N=C(NH2)2 a drugi supstituenti se kao što je definisano u opisu su urokinazni (uPA) inhibitori.[Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is H and the other is N=C(NH2)2 or NHC(=NH)NH2, and the other substituents are as defined herein, are urokinase (uPA) inhibitors.
YU21100A 1997-10-16 1998-10-05 Izohinolini kao urokinazni inhibitori YU21100A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721964.6A GB9721964D0 (en) 1997-10-16 1997-10-16 Isoquinolines

Publications (1)

Publication Number Publication Date
YU21100A true YU21100A (sh) 2002-11-15

Family

ID=10820680

Family Applications (1)

Application Number Title Priority Date Filing Date
YU21100A YU21100A (sh) 1997-10-16 1998-10-05 Izohinolini kao urokinazni inhibitori

Country Status (41)

Country Link
US (1) US6248738B1 (sh)
EP (1) EP1023268B1 (sh)
JP (1) JP3600794B2 (sh)
KR (1) KR20010031163A (sh)
CN (1) CN1275979A (sh)
AP (1) AP959A (sh)
AR (1) AR015964A1 (sh)
AT (1) ATE240943T1 (sh)
AU (1) AU727315B2 (sh)
BG (1) BG104328A (sh)
BR (1) BR9812922A (sh)
CA (1) CA2306782C (sh)
CO (1) CO4990959A1 (sh)
DE (1) DE69814894T2 (sh)
DK (1) DK1023268T3 (sh)
DZ (1) DZ2624A1 (sh)
EA (1) EA002632B1 (sh)
ES (1) ES2197514T3 (sh)
GB (1) GB9721964D0 (sh)
GT (1) GT199800159A (sh)
HN (1) HN1998000158A (sh)
HR (1) HRP20000217A2 (sh)
HU (1) HUP0004491A3 (sh)
ID (1) ID23913A (sh)
IL (1) IL135122A0 (sh)
IS (1) IS5412A (sh)
MA (1) MA26552A1 (sh)
NO (1) NO20001924L (sh)
NZ (1) NZ503390A (sh)
OA (1) OA11348A (sh)
PA (1) PA8461601A1 (sh)
PE (1) PE121299A1 (sh)
PL (1) PL340035A1 (sh)
PT (1) PT1023268E (sh)
SK (1) SK4872000A3 (sh)
TN (1) TNSN98185A1 (sh)
TR (1) TR200001010T2 (sh)
UY (2) UY25211A1 (sh)
WO (1) WO1999020608A1 (sh)
YU (1) YU21100A (sh)
ZA (1) ZA989412B (sh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005214A2 (en) * 1998-07-24 2000-02-03 Pfizer Inc. Isoquinolines as urokinase inhibitors
DE19940389A1 (de) 1999-08-25 2001-03-01 Wilex Biotechnology Gmbh Selektive Inhibitoren des Urokinase-Plasminogen Aktivators
ES2172376B1 (es) * 2000-01-28 2003-11-16 Servier Lab Nuevos derivados de isoquinoleinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE10013715A1 (de) 2000-03-20 2001-09-27 Wilex Biotechnology Gmbh Hochselektive Inhibitoren des Urokinase-Plasminogenaktivators
GB0026490D0 (en) * 2000-10-30 2000-12-13 Pfizer Ltd Process
JP2005500284A (ja) * 2001-06-11 2005-01-06 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｐ３８のイソキノリンインヒビター
UA80131C2 (en) 2002-05-28 2007-08-27 Dimensional Pharm Inc Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
SI1564210T1 (sl) * 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
GB0326964D0 (en) * 2003-11-19 2003-12-24 Glaxo Group Ltd Chemical compounds
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
WO2006090783A1 (ja) * 2005-02-25 2006-08-31 Kowa Co., Ltd. ４－フルオロイソキノリン－５－スルホニルハライド又はその塩の製造方法
ES2329286T3 (es) 2005-06-24 2009-11-24 Wilex Ag Uso de inhibidores de uroquinasa para el tratamiento y/o la prevencion de enfermedades neuropatologicas.
JP4669040B2 (ja) * 2006-03-06 2011-04-13 日本たばこ産業株式会社 ４−オキソキノリン化合物の製造方法
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
CN106831575B (zh) * 2017-02-13 2019-04-16 北京六合宁远科技有限公司 一种1-氨基异喹啉-6-甲醇的制备方法
CN113877483B (zh) * 2021-07-20 2023-11-24 烟台宁远药业有限公司 医药中间体卤代异喹啉类硼酸的低温连续合成装置与方法
CN115286573B (zh) * 2022-08-04 2024-12-10 常州工程职业技术学院 一种1-烷氧基异喹啉化合物的绿色合成方法

Also Published As

Publication number Publication date
ATE240943T1 (de) 2003-06-15
HUP0004491A2 (en) 2001-03-28
IL135122A0 (en) 2001-05-20
BG104328A (bg) 2000-12-29
CA2306782A1 (en) 1999-04-29
EP1023268A1 (en) 2000-08-02
ZA989412B (en) 2000-04-17
DK1023268T3 (da) 2003-06-10
DE69814894D1 (de) 2003-06-26
UY25211A1 (es) 2000-12-29
IS5412A (is) 2000-03-21
SK4872000A3 (en) 2001-12-03
PL340035A1 (en) 2001-01-15
AP9801366A0 (en) 1998-12-31
ID23913A (id) 2000-05-25
BR9812922A (pt) 2000-08-08
PE121299A1 (es) 1999-12-01
DE69814894T2 (de) 2003-12-24
TNSN98185A1 (fr) 2005-03-15
EP1023268B1 (en) 2003-05-21
EA002632B1 (ru) 2002-08-29
EA200000320A1 (ru) 2000-10-30
DZ2624A1 (fr) 2003-03-08
AU1150899A (en) 1999-05-10
HRP20000217A2 (en) 2000-10-31
GT199800159A (es) 2000-04-01
JP3600794B2 (ja) 2004-12-15
GB9721964D0 (en) 1997-12-17
TR200001010T2 (tr) 2000-09-21
NO20001924D0 (no) 2000-04-13
ES2197514T3 (es) 2004-01-01
CN1275979A (zh) 2000-12-06
AU727315B2 (en) 2000-12-07
HUP0004491A3 (en) 2002-10-28
HN1998000158A (es) 1999-02-09
CA2306782C (en) 2005-05-17
AR015964A1 (es) 2001-05-30
NO20001924L (no) 2000-06-15
PT1023268E (pt) 2003-09-30
NZ503390A (en) 2002-03-28
US6248738B1 (en) 2001-06-19
CO4990959A1 (es) 2000-12-26
KR20010031163A (ko) 2001-04-16
WO1999020608A1 (en) 1999-04-29
OA11348A (en) 2003-12-18
MA26552A1 (fr) 2004-12-20
UY25291A1 (es) 1999-07-19
PA8461601A1 (es) 2000-05-24
JP2001520221A (ja) 2001-10-30
AP959A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
YU21100A (sh) Izohinolini kao urokinazni inhibitori
AU6645998A (en) Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
MY119820A (en) Guanidine mimics as factor xa inhibitors
AP2002002637A0 (en) Novel piperazine
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
YU41801A (sh) Derivati fenilglicina
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
CA2078790A1 (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
BG106013A (en) New compounds and compositions as protease inhibitors
NZ514662A (en) Amine derivatives
TR200002605T2 (tr) Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
CA2176935A1 (fr) Arylpiperazines derivees d'indole comme ligands pour les recepteurs 5 ht1-like 5 ht1b et 5 ht1d
DE69631692D1 (de) Amidino proteaseinhibitoren
TW223630B (en) Retroviral protease inhibitors
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
SI1086096T1 (en) Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
MX9708452A (es) Inhibidores de sialidasa bacteriana y metodos para fabricar y usar la misma.
IL131581A0 (en) Cycloalkylalkanecarboxamides and the production and use thereof
MXPA98002443A (es) Inhibidores de guanidino proteasas.
DE69625505D1 (de) Guanidino proteiase inhibitoren
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
MY132057A (en) Quinoxalinones, a process for their preparation and their use
ES2093091T3 (es) Derivado de glutation.
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
AP2002002595A0 (en) Heterocyclic amide derivatives.